Pegcetacoplan for C3G and primary (idiopathic) IC-MPGN: 52-week results from the phase 3 VALIANT trial show sustained efficacy (ERA 2025 C3G) - Apellis Medical Hub

Home / Congress Presentations / C3G and Primary IC-MPGN / ERA 2025

Pegcetacoplan for C3G and primary (idiopathic) IC-MPGN: 52-week results from the phase 3 VALIANT trial show sustained efficacy

Share Via Email

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.